Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas

Modern Pathology

Volumn 26, Issue 4, 2013, Pages 553-562

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

claudin 4; h caldesmon; immunohistochemistry; PAX2; PAX8; peritoneal mesothelioma; serous carcinoma

Indexed keywords

BIOLOGICAL MARKER; CALDESMON; CLAUDIN 4; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX8;

ARTICLE; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PAPILLARY SEROUS CARCINOMA; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

CALMODULIN-BINDING PROTEINS; CLAUDIN-4; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; PAIRED BOX TRANSCRIPTION FACTORS; PAX2 TRANSCRIPTION FACTOR; PERITONEAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84876469892     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.200     Document Type: Article

References (64)

1. Ordónez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol, advance online publication, 7 September 2012 (e-pub ahead of print).
2. Bollinger DJ, Wick MR, Dehner LP, et al. Peritoneal malignant mesothelioma versus serous papillary ade-nocarcinoma: A histochemical and immunohistochem-ical comparison. Am J Surg Pathol 1989;13:659-670. (Pubitemid 19185451)
3. Khoury N, Raju U, Crissman JD, et al. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. Hum Pathol 1990;21:811-819. (Pubitemid 20250565)
4. Wick MR, Mills SE, Swanson PE. Expression of "myelomonocytic" antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol 1990;94:18-26. (Pubitemid 20206890)
5. Ordónez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-1214.
6. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002;40:237-244. (Pubitemid 34227114)
7. Barnetson RJ, Burnett RA, Downie I, et al. Immuno-histochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum. Antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006;125:67-76. (Pubitemid 43089727)
8. Ordónez NG. The diagnostic utility of immunohisto-chemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: A comparative study. Mod Pathol 2006;19: 34-48.
9. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007;31:1139-1148. (Pubitemid 47207115)
10. Takeshima Y, Amatya VJ, Kushitani K, et al. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol 2008;130: 771-779.
11. Ordónez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol 2005;36:1163-1167.
12. Facchetti F, Lonardi S, Gentili F, et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 2007;451: 669-680. (Pubitemid 47340982)
13. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010;34:627-635.
14. Gao FF, Krasinskas AM, Chivukula M. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin? Appl Immunohistochem Mol Morphol 2012;20:272-276.
15. Ordónez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol 2012;19:140-151.
16. Ordónez NG. Value of PAX2 immunostaining in tumor diagnosis: A review and update. Adv Anat Pathol 19:401-409.
17. Gruss P, Walther C. Pax in development. Cell 1992;69:719-722.
18. Mansouri A, Hallonet M, Gruss P. Pax genes and their roles in cell differentiation and development. Curr Opin Cell Biol 1996;8:851-857. (Pubitemid 26399946)
19. Dahl E, Koseki H, Balling R. Pax genes and organogen-esis. Bioessays 1997;19:755-765.
20. Lang D, Powell SK, Plummer RS, et al. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 2007;73:1-14. (Pubitemid 44868976)
21. Stoykova A, Gruss P. Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J Neurosci 1994;14:1395-1412. (Pubitemid 24079992)
22. Mittag J, Winterhager E, Bauer K, et al. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007;148:719-725. (Pubitemid 46143173)
23. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007;104:331-337. (Pubitemid 46135661)
24. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
25. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008;32:1566-1571.
26. Lotan TL, Ye H, Melamed J, et al. Immunohistochem-ical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol 2009; 33:1037-1041.
27. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and meta-static tumors: a comprehensive immunohistochemical study. Mod Pathol 2011;24:751-764.
28. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2011;19:293-299.
29. Ozcan A, Liles N, Coffey D, et al. PAX2 and PAX8 expression in primary and metastatic mü llerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol 2011;35:1837-1847.
30. Tong GX, Devaraj K, Hamele-Bena D, et al. Pax8: a marker for carcinoma of Müllerian origin in serous effusions. Diagn Cytopathol 2011;39:567-574.
31. Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions. Diagn Cytopathol 2011;39:651-656.
32. Zhao L, Guo M, Sneige N, et al. Value of PAX8 and WT1 immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens. Am J Clin Pathol 2012;137:304-309.
33. Torres M, Gómez-Pardo E, Dressler GR, et al. Pax-2 controls multiple steps of urogenital development. Development 1995;121:4057-4065. (Pubitemid 26007357)
34. Dressler GR, Woolf AS. Pax2 in development and renal disease. Int J Dev Biol 1999;43:463-468.
35. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin? Mod Pathol 2007;20:856-863. (Pubitemid 47077268)
36. Chivukula M, Dabbs DJ, O'Connor S, et al. PA X 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma. Int J Gynecol Pathol 2009;28:570-578.
37. Sharma SG, Gokden M, McKenney JK, et al. The utility of PAX-2 and renal cell carcinoma marker immuno-histochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol 2010;18:494-498.
38. Zhai QJ, Ozcan A, Hamilton C, et al. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: a comprehensive immunohisto-chemical study. Appl Immunohistochem Mol Morphol 2010;18:323-332.
39. Gokden N, Gokden M, Phan DC, et al. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immuno-histochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol 2008;32: 1462-1467.
40. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocar-cinoma to body fluids. Am J Clin Pathol 2002;117: 745-750. (Pubitemid 34457009)
41. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including car-cinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002;21:11-15. (Pubitemid 34008347)
42. Nofech-Mozes S, Khalifa MA, Ismiil N, et al. Immu-nophenotyping of serous carcinoma of the female genital tract. Mod Pathol 2008;21:1147-1155.
43. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476-481. (Pubitemid 41646604)
44. Wang NS, Huang SN, Gold P. Absence of carcinoem-bryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers. Cancer 1979;44:937-943. (Pubitemid 10242226)
45. Ordónez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002;33:953-967.
46. Ordónez NG. What are the current best immunohisto-chemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007;38:1-16.
47. González-Mariscal L, Betanzos A, Nava P, et al. Tight junction proteins. Prog Biophys Mol Biol 2003;81: 1-44. (Pubitemid 35436609)
48. Cereijido M, Valdés J, Shoshani L, et al. Role of tight junctions in establishing and maintaining cell polarity. Annu Rev Physiol 1998;60:161-177. (Pubitemid 28157869)
49. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 2004;286:C1213-C1228. (Pubitemid 38649971)
50. Lódi C, Szabó E, Holczbauer A, et al. Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Mod Pathol 2006;19:460-469. (Pubitemid 43277001)
51. Soini Y, Kinnula V, Kahlos K, et al. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol 2006;59:250-254. (Pubitemid 43344884)
52. Choi YL, Kim J, Kwon MJ, et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 2007;22:1185-1195. (Pubitemid 47470312)
53. Lonardi S, Manera C, Marucci R, et al. Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions. Diagn Cytopathol 2011;39:313-317.
54. Yoshida H, Sumi T, Zhi X, et al. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer. Anticancer Res 2011;31:1271-1277.
55. Collins CL, Ordónez NG, Schaefer R, et al. Thrombo-modulin expression in malignant pleural mesothelio-ma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827-833.
56. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046. (Pubitemid 26276924)
57. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105-110. (Pubitemid 40128102)
58. Ueki N, Sobue K, Kanda K, et al. Expression of high and low molecular weight caldesmons during pheno-typic modulation of smooth muscle cells. Proc Natl Acad Sci USA 1987;84:9049-9053.
59. Glukhova MA, Frid MG, Koteliansky VE. Developmental changes in expression of contractile and cytoskeletal proteins in human aortic smooth muscle. J Biol Chem 1990;265:13042-13046.
60. Sobue K, Sellers JR. Caldesmon, a novel regulatory protein in smooth muscle and nonmuscle actomyosin systems. J Biol Chem 1991;266:12115-12118. (Pubitemid 21907062)
61. Wang C-LA. Caldesmon and smooth-muscle regulation. Cell Biochem Biophys 2001;35:275-288. (Pubitemid 33614134)
62. Dabrowska R, Kulikova N, Gagola M. Nonmuscle caldesmon: its distribution and involvement in various cellular processes. Protoplasma 2004; 224: 1-13. (Pubitemid 39403881)
63. Comin CE, Dini S, Novelli L, et al. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am J Surg Pathol 2006;30:463-469. (Pubitemid 43740147)
64. Husain AN, Colby T, Ordónez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med, advance online publication, 28 August 2012 (e-pub ahead of print).